Maternal Schedule of Evaluation

Slides:



Advertisements
Similar presentations
ASPIRE Off-Site Visits. Rationale Why make an allowance for off-site visits in the protocol? Adherence & Retention Off-site visits Improving Clinic Flow.
Advertisements

HIV Counselling and Testing
EDRN’s Validation Study Information Management System Developed for EDRN by the DMCC Cancer Biomarkers Group Division of Cancer Prevention Jet Propulsion.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
S AFETY OF I SONIAZID P REVENTIVE T HERAPY A MONG HIV- INFECTED P REGNANT W OMEN IN H IGH TB I NCIDENCE S ETTINGS : STUDY UPDATE OF IMPAACT P1078 (APPRISE)
Unit 5: IPT Isoniazid TB Preventive Therapy
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
DRAFT BHIVA GUIDELINES Routine monitoring of HIV UK-CAB 31 July 2009 Matt Williams writing committee community rep.
Program Collaboration and Service Integration: An NCHHSTP Green paper Kevin Fenton, M.D., Ph.D., F.F.P.H. Director National Center for HIV/AIDS, Viral.
Tuberculosis Research of INA-RESPOND on Drug-resistant
MTN-028 Laboratory Training May Beamer, Lorna Rabe MTN Laboratory Center Magee-Womens Research Institute Pittsburgh, PA.
MTN-027 Laboratory Related CRFs. Pharmacokinetics Specimens (PKS-1) - Enrollment, Day 28 Pharmacokinetics Specimens (PKD-1) - Days 1, 2, 3, 7, 14, 21,
1 Monitoring The Patient on ARV Treatment HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Preparing for Cohort Review & Standard Forms for Cohort Presentation June 16, 2010 Kieran Hartsough.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners “Thibelo TB” Aurum Health Research LSHTM JHU Gold.
1 Management, Care for infants who were born from infected mothers HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
MTN-028 Laboratory Related CRFs. Pharmacokinetics Specimens (PKS-1) - Enrollment, Day 28 Pharmacokinetics Specimens (PKD-1) - Days 1, 2, 3, 7, 14, 21,
CHLAMYDIA / GONORRHEA Vaginal Specimen Collection and Form Training NC State Laboratory of Public Health 2015.
Maternal clinical considerations
IMPAACT 2010 Eligibility Criteria
Maternal Toxicity Management
Maternal clinical considerations
IMPAACT 2010 Protocol Specifications for Recruitment, Screening, and Enrollment No updates.
HOW TO SCREEN PATIENTS AND BOOK THE BASELINE VISIT APPOINTMENT?
Clinical Case Scenarios
Management of the Newborn When Maternal TB Suspected
IMPAACT 2010 Screening Visits
CEDAR and SEQUOIA Protocol Amendment Summary
IMPAACT P1078 Eligibility Criteria
Overview of Visit Scheduling and Types of Follow-up Visits SCHARP
IMPAACT 2010 Screening Visits
HOPE SSP Updates May 2017.
IMPAACT 2010 Eligibility Criteria
VESTED Quiz Game
Infant clinical considerations
A protocol in development IMPAACT Prevention Scientific Committee
2017 Key Considerations for adolescents and children & Key populations
Clinical Case Scenarios
MTN-036 Study of Extended Duration Dapivirine Vaginal Ring for HIV Prevention How do I know if I’m Eligible to join? Women who join the study must.
VESTED Quiz Game
Maternal Toxicity Management
Module 4 (a) Getting started on PrEP
Treatment of Latent TB Infection (LTBI)
Maternal Toxicity Management
Maternal clinical considerations
Protocol References Section Title 6.2 Entry Visit 5.1
Clinical Case Scenarios
Clinical Case Scenarios
EDRN’s Validation Study Information Management System
Protocol References Section Title 6.2 Entry Visit 5.1
IMPAACT 2010 Eligibility Criteria
IMPAACT 2010 Eligibility Criteria
IMPAACT 2010 Screening Visits
Expedited Adverse Event Reporting Requirements
What’s New in the Perinatal Guidelines
IMPAACT 2010 Pharmacy, Study Drug, and Concomitant Medication Considerations at Entry No updates.
MTN-037 Screening and Enrollment
Overview.
Follow-up Visit Considerations
World Health Organization
Overview of Enrollment Procedures
Charles Gilks HIV Department, WHO
MTN-037 Protocol Overview
Example of A* A (4,0) 4 OPEN: (A4) CLOSED: ().
Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:
Thrombophilia in pregnancy: Whom to screen, when to treat
Guideline for the Treatment of Alcohol Use Disorder in the Outpatient Setting with Intramuscular Naltrexone Assess Candidacy for IM Naltrexone Meets DMS-V.
5th edition NTP MANUAL OF PROCEDURES Case Finding
Presentation transcript:

Maternal Schedule of Evaluation P1078 Appendix I-A Version 2.0

Week 4 antepartum and L/D visit windows widened What is the V2 target window for the L/D visit? What is the V2 allowable window for the L/D visit? Days 0-5 Days 0-14

Footnote 2 Added

Footnote 3 updated

Updated to include all footnotes related to Suspected Active TB Visits (including M.tb. AFB smear and isolate storage)

Footnote 5 updated

Clarified timing of WHO clinical staging for HIV and added assessment of signs/symptoms of neurocognitive impairment

Removed

Footnote 11 updated

When should the TST be read? Exactly 72 hours after placement 2-3 days after placement Up to 7 days after placement Ideally Allowable

Allowed sites to perform TST at Week 4 postpartum, if not done at L/D visit Standardized time that TST should IDEALLY be read (2-3 days after placement) and provided allowable window (up to 7 days after placement)

Added row to indicate additional required counseling related to signs and symptoms of INH side effects

Moved to laboratory evaluations Increased allowable blood volume Testing requirements in eligibility criteria have been updated

Frequency reduced

Rows merged and footnote updated

Glucose and creatinine only assessed at screening

Footnote 16 updated

If HIV viral load assessed as part of screening, result may be used for confirmation and Entry assessments

Detail moved from footnote to table Updated to allow urine or serum testing Required only when pregnancy is suspected

Updated footnote and clarified “(Heparin)”

Increased the number of women to be potentially selected for viable PBMC collection: Entry: from 500 women to 700 women (TB ELISPOT from 260 women to 460 women) Postpartum Weeks 12 and 44: from 260 women to 460 women Postpartum Week 48: no change

Removed maternal urine storage and Hepatitis C testing

Added serum collection at entry

Updated footnote

Clarified text for consistency Clarified that QGIT should not be collected if participant already determined to have suspected or confirmed TB Reduced number of women to be potentially selected for storage of QGIT supernatants

Added hair collection

Clarified PK collection timepoints and expanded visit windows